Company news

Vertex Pharmaceuticals Incorporated news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Vertex and Verve Therapeutics Establish Collaboration to Discover and Develop an In Vivo Gene Editing Program for Liver Disease

July 19, 2022

Vertex to Announce Second Quarter 2022 Financial Results on August 4

July 17, 2022

Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes

July 10, 2022

Vertex Announces Letter of Intent With the pan-Canadian Pharmaceutical Alliance for Public Reimbursement of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 and Older

July 7, 2022

Vertex Announces FDA Has Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes

July 4, 2022

Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress

June 10, 2022

Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at the European Cystic Fibrosis Conference

June 9, 2022

Vertex to Participate in the Goldman Sachs 43rd Annual Healthcare Conference on June 15

June 7, 2022

Vertex Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation by U.S. FDA and Priority Medicines (PRIME) Designation by the EMA

June 7, 2022

Vertex Presents New Data from VX-880 Phase 1/2 Clinical Trial at the American Diabetes Association 82nd Scientific Sessions

June 5, 2022

Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001™ at the 2022 Annual European Hematology Association (EHA) Congress

June 1, 2022

Vertex to Present New Data on VX-880 Clinical Trial at 82nd American Diabetes Association Annual Conference

May 30, 2022

Suketu Upadhyay Elected to Vertex Board of Directors

May 17, 2022

Vertex Announces Further Expansion in the Boston Seaport at Dedication of the Jeffrey Leiden Center for Cell and Genetic Therapies

May 16, 2022

Vertex Announces $50 Million Commitment to Health Equity With Three Initial Grants

May 16, 2022

Vertex Reports First Quarter 2022 Financial Results

May 4, 2022

Vertex to Announce First Quarter 2022 Financial Results on May 5

April 20, 2022

Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 Through 11 years With At Least One F508del Mutation

April 20, 2022

Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 Through 11 years With At Least One F508del Mutation

April 19, 2022

Vertex Announces Statistically Significant and Clinically Meaningful Results From Two Phase 2 Proof-of-Concept Studies of VX-548 for the Treatment of Acute Pain

March 30, 2022

Vertex Announces Reimbursement Agreement in Australia for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for Patients With Cystic Fibrosis Ages 12 Years and Older With at Least One F508del Mutation in the CFTR Gene

March 25, 2022

Health Canada Grants Marketing Authorization for KALYDECO® (ivacaftor) for Patients With Cystic Fibrosis Between the Ages of 4 Months and 18 Years With the R117H Mutation in the CFTR Gene

March 25, 2022

Vertex Advances VX-147 Into Pivotal Clinical Development for People With APOL1-Mediated Kidney Disease

March 21, 2022

Vertex to Present at Cowen’s 42nd Annual Health Care Conference on March 8

February 28, 2022

Vertex Reports Fourth Quarter 2021 and Full Year Financial Results

January 25, 2022

Vertex to Announce Fourth Quarter 2021 Financial Results on January 26

January 17, 2022

European Commission Approves KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Children With Cystic Fibrosis Ages 6 to 11 Years

January 10, 2022

Vertex to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 10

January 3, 2022

Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis

November 30, 2021

Vertex Announces Reimbursement Agreement in Spain for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With Cystic Fibrosis 12 Years and Older With At Least One F508del Mutation in the CFTR Gene

November 18, 2021

Vertex Receives CHMP Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor in Children With Cystic Fibrosis Ages 6 Through 11

November 11, 2021

Vertex Reports Third-Quarter 2021 Financial Results

November 1, 2021

Vertex's Supplement to a New Drug Submission for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Patients Ages 6-11 Accepted for Priority Review by Health Canada

October 27, 2021

Vertex and Mammoth Biosciences Announce Collaboration to Develop In Vivo Gene-Editing Therapies for Serious Diseases

October 25, 2021

Vertex to Announce Third-Quarter 2021 Financial Results on November 2

October 21, 2021

Vertex to Present Long-Term Data Demonstrating Significant Benefits of Treatment With CFTR Modulators at North American Cystic Fibrosis Conference (NACFC)

October 18, 2021

Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes

October 17, 2021

Vertex's Supplement to a New Drug Submission for KALYDECO® (ivacaftor) for Patients with Cystic Fibrosis Between the Ages of 4 Months and 18 Years with the R117H Mutation in the CFTR Gene Accepted for Priority Review by Health Canada

September 22, 2021

Vertex Announces Letter of Intent With pan-Canadian Pharmaceutical Alliance for Public Reimbursement of CFTR Modulators Extended to Include TRIKAFTA®(elexacaftor/tezacaftor/ivacaftor and ivacaftor)

September 17, 2021

Vertex to Present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on September 15th

September 12, 2021

Vertex Announces Publication in The New England Journal of Medicine of Phase 3 Results for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People With Cystic Fibrosis

August 25, 2021

Health Canada Grants Marketing Authorization for KALYDECO® (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants With CF as Early as Four Months of Age

August 25, 2021

Vertex and Arbor Biotechnologies Establish New Partnership to Develop Novel ex vivo Engineered Cell Therapies

August 23, 2021

Vertex Appoints Stuart A. Arbuckle as Chief Operating Officer

August 3, 2021

Vertex Reports Second-Quarter 2021 Financial Results

July 28, 2021

Vertex to Initiate Phase 3 Development Program for New Once-Daily Triple Combination Regimen in People With Cystic Fibrosis

July 27, 2021

Vertex Initiates Phase 2 Clinical Trial Program for VX-548 for the Treatment of Acute Pain

July 18, 2021

Vertex to Announce Second-Quarter 2021 Financial Results on July 29

July 15, 2021

Vertex Announces National Reimbursement Agreement in France for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) and SYMKEVI® (tezacaftor/ivacaftor) for Eligible Cystic Fibrosis Patients

June 27, 2021

Vertex Announces New Portfolio Reimbursement Agreement in Italy Including KAFTRIO®, SYMKEVI® and Additional Indications of ORKAMBI® and KALYDECO® for Eligible Patients With Cystic Fibrosis

June 24, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 32 calls. Every call is listed under its year.

Decks

The 5 newest of 20 decks. Every deck is listed under its year.